These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 25786335)
41. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer. Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784 [TBL] [Abstract][Full Text] [Related]
42. Feasibility Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (150 mg/m Kojima Y; Kawamoto H; Nishikawa T; Hayami R; Shimo A; Haku E; Akiyama K; Tsugawa K Clin Breast Cancer; 2018 Oct; 18(5):374-379. PubMed ID: 29452759 [TBL] [Abstract][Full Text] [Related]
43. Effectiveness and Tolerability of Nab-paclitaxel in Younger versus Elderly Patients With Metastatic HR-positive/HER2-negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO. Potthoff K; Stötzer O; Söling U; Hansen R; Harde J; Dille S; Nusch A; Marschner N Clin Breast Cancer; 2020 Jun; 20(3):e315-e326. PubMed ID: 32273207 [TBL] [Abstract][Full Text] [Related]
44. Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results. O'Reilly EM; Roach J; Miller P; Yu KH; Tjan C; Rosano M; Krause S; Avery W; Wolf J; Flaherty K; Nix D; Ryan DP Oncologist; 2017 Dec; 22(12):1429-e139. PubMed ID: 29158367 [TBL] [Abstract][Full Text] [Related]
45. A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer. Huang D; Ba Y; Xiong J; Xu N; Yan Z; Zhuang Z; Yu Z; Wan H; Zhang Y; Deng T; Zheng R; Guo Z; Hu C; Wang M; Yu Z; Yao Y; Meng J Eur J Cancer; 2013 Sep; 49(14):2995-3002. PubMed ID: 23810466 [TBL] [Abstract][Full Text] [Related]
46. A phase I combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer. Hokita S; Aikou T; Miyazono F; Ishigami S; Aridome K; Maenohara S; Saihara T; Suenaga K; Nomura H; Maeda S; Takatori H; Arima H; Uchikado Y; Natsugoe S; Takao S Cancer Chemother Pharmacol; 2006 Jun; 57(6):736-40. PubMed ID: 16163539 [TBL] [Abstract][Full Text] [Related]
47. Safety and Efficacy of Camrelizumab in Combination With Nab-Paclitaxel Plus S-1 for the Treatment of Gastric Cancer With Serosal Invasion. Lin JL; Lin JX; Lin JP; Zheng CH; Li P; Xie JW; Wang JB; Lu J; Chen QY; Huang CM Front Immunol; 2021; 12():783243. PubMed ID: 35116023 [TBL] [Abstract][Full Text] [Related]
48. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA; Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121 [TBL] [Abstract][Full Text] [Related]
49. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614 [TBL] [Abstract][Full Text] [Related]
50. Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer. He MM; Wang F; Jin Y; Yuan SQ; Ren C; Luo HY; Wang ZQ; Qiu MZ; Wang ZX; Zeng ZL; Li YH; Wang FH; Zhang DS; Xu RH Cancer Sci; 2018 Nov; 109(11):3575-3582. PubMed ID: 30281875 [TBL] [Abstract][Full Text] [Related]
51. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial. Takashima T; Mukai H; Hara F; Matsubara N; Saito T; Takano T; Park Y; Toyama T; Hozumi Y; Tsurutani J; Imoto S; Watanabe T; Sagara Y; Nishimura R; Shimozuma K; Ohashi Y; Lancet Oncol; 2016 Jan; 17(1):90-8. PubMed ID: 26617202 [TBL] [Abstract][Full Text] [Related]
52. Neoadjuvant chemotherapy for breast cancer with weekly nab-paclitaxel followed by epirubicin and cyclophosphamide--results of a case series. Hahn A; Schlotter CM; Rossmanith WG; Ulmer HU; Staiger HJ; Villena C In Vivo; 2014; 28(2):235-41. PubMed ID: 24632979 [TBL] [Abstract][Full Text] [Related]
53. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Untch M; Jackisch C; Schneeweiss A; Conrad B; Aktas B; Denkert C; Eidtmann H; Wiebringhaus H; Kümmel S; Hilfrich J; Warm M; Paepke S; Just M; Hanusch C; Hackmann J; Blohmer JU; Clemens M; Darb-Esfahani S; Schmitt WD; Dan Costa S; Gerber B; Engels K; Nekljudova V; Loibl S; von Minckwitz G; ; Lancet Oncol; 2016 Mar; 17(3):345-356. PubMed ID: 26869049 [TBL] [Abstract][Full Text] [Related]
54. Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer. Mei Y; Shi M; Zhu Z; Yuan H; Yan C; Li C; Feng T; Yan M; Zhang J; Zhu Z Future Oncol; 2022 Jan; 18(2):139-148. PubMed ID: 34877867 [TBL] [Abstract][Full Text] [Related]
55. Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study. Kojima Y; Yoshie R; Kawamoto H; Shimo A; Uejima T; Iwatani T; Motoyoshi A; Kanemaki Y; Boku N; Tsugawa K Oncology; 2019; 96(6):309-317. PubMed ID: 30893699 [TBL] [Abstract][Full Text] [Related]
56. Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer. Takahashi I; Emi Y; Kakeji Y; Tokunaga E; Ushiro S; Oki E; Watanabe M; Baba H; Maehara Y Oncol Rep; 2006 Apr; 15(4):849-54. PubMed ID: 16525670 [TBL] [Abstract][Full Text] [Related]
57. A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma. Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakagawa N; Takahashi S; Ohge H; Sueda T Cancer Chemother Pharmacol; 2017 Apr; 79(4):775-781. PubMed ID: 28293715 [TBL] [Abstract][Full Text] [Related]
58. A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial. Gennari A; Sun Z; Hasler-Strub U; Colleoni M; Kennedy MJ; Von Moos R; Cortés J; Vidal MJ; Hennessy B; Walshe J; Parraga KA; Ribi K; Bernhard J; Murillo SM; Pagani O; Barbeaux A; Borstnar S; Rabaglio-Poretti M; Maibach R; Regan MM; Jerusalem G; Ann Oncol; 2018 Mar; 29(3):661-668. PubMed ID: 29228091 [TBL] [Abstract][Full Text] [Related]
59. Feasibility Study of Nanoparticle Albumin-Bound-Paclitaxel and S-1 Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With Operable Breast Cancer: A Prospective Study. Seki H; Higeta K; Sakurai T; Sakurada A; Kinoshita T; Shimizu K Clin Breast Cancer; 2022 Apr; 22(3):235-243. PubMed ID: 34289949 [TBL] [Abstract][Full Text] [Related]
60. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]